Temozolomide and treatment of malignant glioma
- PMID: 10914698
Temozolomide and treatment of malignant glioma
Abstract
Malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) occur more frequently than other types of primary central nervous system tumors, having a combined incidence of 5-8/100,000 population. Even with aggressive treatment using surgery, radiation, and chemotherapy, median reported survival is less than 1 year. Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors. Temozolomide, a p.o. imidazotetrazine second-generation alkylating agent, is the leading compound in a new class of chemotherapeutic agents that enter the cerebrospinal fluid and do not require hepatic metabolism for activation. In vitro, temozolomide has demonstrated schedule-dependent antitumor activity against highly resistant malignancies, including high-grade glioma. In clinical studies, temozolomide consistently demonstrates reproducible linear pharmacokinetics with approximately 100% p.o. bioavailability, noncumulative minimal myelosuppression that is rapidly reversible, and activity against a variety of solid tumors in both children and adults. Preclinical studies have evaluated the combination of temozolomide with other alkylating agents and inhibitors of the DNA repair protein O6-alkylguanine alkyltransferase to overcome resistance to chemotherapy in malignant glioma and malignant metastatic melanoma. Temozolomide has recently been approved in the United States for the treatment of adult patients with refractory anaplastic astrocytoma and, in the European Union, for treatment of glioblastoma multiforme showing progression or recurrence after standard therapy. Predictable bioavailability and minimal toxicity make temozolomide a candidate for a wide range of clinical testing to evaluate the potential of combination treatments in different tumor types. An overview of the mechanism of action of temozolomide and a summary of results from clinical trials in malignant glioma are presented here.
Similar articles
-
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.Molecules. 2009 Apr 16;14(4):1561-77. doi: 10.3390/molecules14041561. Molecules. 2009. PMID: 19384285 Free PMC article. Review.
-
Temozolomide: a milestone in neuro-oncology and beyond?Expert Rev Anticancer Ther. 2006 Aug;6(8):1187-204. doi: 10.1586/14737140.6.8.1187. Expert Rev Anticancer Ther. 2006. PMID: 16925485 Review.
-
Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.Ideggyogy Sz. 2004 Nov 20;57(11-12):394-9. Ideggyogy Sz. 2004. PMID: 15662767 Clinical Trial.
-
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.Semin Oncol. 2000 Jun;27(3 Suppl 6):35-40. Semin Oncol. 2000. PMID: 10866348 Review.
-
Temozolomide in malignant gliomas.Semin Oncol. 2000 Jun;27(3 Suppl 6):27-34. Semin Oncol. 2000. PMID: 10866347 Review.
Cited by
-
Unveiling the Pharmacological Role of Human Deubiquitinating Enzymes in Temozolomide Response of Glioblastoma Cells.Cell Biochem Biophys. 2024 May 29. doi: 10.1007/s12013-024-01325-6. Online ahead of print. Cell Biochem Biophys. 2024. PMID: 38809352
-
Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma.J Nanobiotechnology. 2024 May 17;22(1):264. doi: 10.1186/s12951-024-02531-3. J Nanobiotechnology. 2024. PMID: 38760771 Free PMC article.
-
GINS2 regulates temozolomide chemosensitivity via the EGR1/ECT2 axis in gliomas.Cell Death Dis. 2024 Mar 11;15(3):205. doi: 10.1038/s41419-024-06586-w. Cell Death Dis. 2024. PMID: 38467631 Free PMC article.
-
Inhibition of glioblastoma cell proliferation and invasion by the choline-kinase inhibitor JAS239 varies with cell type and hypoxia.bioRxiv [Preprint]. 2024 Jan 20:2024.01.17.576078. doi: 10.1101/2024.01.17.576078. bioRxiv. 2024. PMID: 38293093 Free PMC article. Preprint.
-
The Role of Progranulin (PGRN) in the Pathogenesis of Glioblastoma Multiforme.Cells. 2024 Jan 10;13(2):124. doi: 10.3390/cells13020124. Cells. 2024. PMID: 38247816 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical